After an Executive Order on Psychedelics, What Comes Next?
Understanding the EO's impact on LSD, psilocybin, 5-MeO-DMT, ibogaine, MDMA.
Updated April 30, 2026 | Reviewed by Monica Vilhauer Ph.D.
The April 18 White House executive order on psychedelics is best understood not as a legalization measure, but a policy shift accelerating treatment development. The Administration framed it explicitly as a mental health initiative—“ Removing barriers to psychedelic drugs "—for serious mental illnesses like PTSD , depression , and addiction
The Executive Office (EO) explicitly frames psychedelics as a response to treatment-resistant mental illness in veterans—PTSD, suicide, depression, and substance use disorders. Military veterans are the primary clinical population around which these federal psychedelic initiatives are organized. The Veterans Health Administration (VHA) is a proving ground—a structured, federally-integrated system where psychedelic therapies can be studied, validated, and potentially deployed under tight controls.
The EO directs coordination between the Department of Veterans Affairs and agencies such as the NIH and the FDA to expand clinical trials and data sharing. The EO encourages veteran participation in clinical trials or expanded access programs, positioning the VA as a controlled- access environment.
Veterans with refractory PTSD, suicidal thoughts, substance abuse , or depression—difficult populations to treat with conventional pharmacotherapy—are prioritized.
The President’s order directs federal agencies to facilitate clinical trial participation, expand access pathways such as Right-to-Try mechanisms, and prioritize regulatory review. This creates real momentum—compressing development timelines, signaling to regulators, researchers, and investors that psychedelics are a federal priority. However, it does not alter statutory requirements for approval: the FDA still requires substantial evidence of safety and efficacy.
The immediate regulatory impact of the EO is already visible. Three companies—Compass Pathways (COMP360 psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD)—received FDA Commissioner’s National Priority Vouchers following the EO. In parallel, the FDA permitted clinical development of DemeRx’s DMX-1001 (oral noribogaine hydrochloride) for treating alcohol use disorder, marking the first U.S. clinical pathway for an ibogaine-derived therapy.
Comments From Experts
At the White House signing and in subsequent comments, Nora Volkow, MD, director of NIDA, said while patient-reported experiences and early benefit signals should be considered, these therapies remain investigational and must be evaluated through meticulous scientific frameworks. Volkow reinforces that the executive order should accelerate research, not substitute for it.
The more pointed caution has come from Yale Chairman, John Krystal, MD, whose critique is rooted in FDA proof standards. His central argument is that psychedelics, despite their promise, are not yet supported by the level of FDA evidence required for routine clinical use, and current policy momentum risks advancing them faster than the data could justify. Krystal’s concern is that psychedelic research deficiencies and expectancy bias may produce overestimates of efficacy that cannot hold up under more rigorous phase III conditions. Research has started to identify predictors of unfavorable responses to psychedelics, including young people, polydrug users, and people with psychosocial stress , apprehension, cognitive preoccupation, or a personal or family history of major psychiatric disorders.
Whether this EO push translates into safe, effective, and scalable therapies will depend on whether the field can meet the same proof-of-concept criteria that govern prior approvals. The history of esketamine suggests standards for highly promising therapies should be demanding, but can be met fully before being responsibly integrated into clinical practice.
Ten FDA Proof Issues for Psychedelics
Lessons From Ketamine
Consider Spravato, a novel rapid-acting CNS intervention whose development from Ketamine benefited from expedited regulatory pathways. Its approval nonetheless required multiple randomized controlled trials, replication across studies, and a substantial safety database. Even then, evidence remained debated, effect sizes were modest, and the drug was approved with a stringent Risk Evaluation and Mitigation Strategy (REMS) mandating in-clinic administration and direct patient monitoring.
Long-term psychedelic safety remains unresolved. Existing datasets are limited in size and duration, adding to uncertainty around the incidence of persistent perceptual disturbances, subtle cognitive or affective changes, and delayed emergence of mood instability, including mania-spectrum disorders.
The REMS model for Spravato has proven that in-clinic administration monitoring requirements, distribution restrictions, and long-term follow-up works.
A central regulatory question for psychedelics is whether a comparable REMS-like infrastructure—requiring supervised dosing sessions, trained personnel, and post-administration monitoring—can be implemented in real-world practice. If such a system proves operationally infeasible, approval may be accompanied by restrictive access conditions.
The EO accelerates the pathway to development, but FDA approval requirements are rigorous demonstration of safety and efficacy through randomized controlled trials.
In practical terms, the Executive Order should quickly expand access to investigational psychedelics through Right-to-Try pathways, particularly for patients with serious or treatment-resistant illnesses without access to clinical trials. However, such access does not substitute for the evidentiary standards required by the FDA. The EO signals a new priority to NIH, which will influence funding allocation and may affect reviewers’ mindsets. Anchoring in the VA system provides an important real-world data infrastructure, large, centralized patient populations, and built-in longitudinal follow-up. This VA partnership could be the big game-changer, materially accelerating evidence generation.
Facebook image: Tayler Derden/Shutterstock
The White House. Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness. Published April 2026. Accessed April 26, 2026. whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/
John Krystal. Expert commentary on risks of accelerated psychedelic drug development. Reported in: The Washington Post . https://www.washingtonpost.com/health/2026/04/20/psychedelic-retreats-m…
FDA Regulatory Standards. US Food and Drug Administration. 21 CFR §314.126: Adequate and well-controlled studies. Revised 2024. Accessed April 26, 2026. https://www.ecfr.gov/current/title-21/section-314.126
US Food and Drug Administration. Expedited programs for serious conditions—drugs and biologics. Guidance for industry. Published 2014. Updated 2023. Accessed April 26, 2026. https://www.fda.gov/media/86377/download
Yale School of Medicine. Ketamine: How Yale Redefined Depression Treatment. February 24, 2026. https://medicine.yale.edu/news-article/ketamine-how-yale-redefined-depr…
Viljoen, G., Bendau, A., Walter, H. et al. Therapist-rated predictors of response to psychedelic-assisted therapy. Nat. Mental Health (2026). https://doi.org/10.1038/s44220-026-00642-4
Share this post Facebook Bluesky Linkedin Email
There was a problem adding your email address. Please try again.
By submitting your information you agree to the Psychology Today Terms & Conditions and Privacy Policy
Mark S. Gold, M.D., is a pioneering researcher, professor, and chairman of psychiatry at Yale, the University of Florida, and Washington University in St Louis.
Get the help you need from a therapist near you–a FREE service from Psychology Today.
This article is part of the Bringwise Psychology Journal — daily insights on human behavior, mental health, and personal growth.